Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 1;11(1):2093054. doi: 10.1080/2162402X.2022.2093054

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Ad-IL15 plays an antitumor role by increasing TILs. Mice were subcutaneously inoculated with B16-F10 or MC-38 cells. When tumors reached approximately 50 mm³, they were directly injected with PBS, Ad (5 × 10⁸ PFU) or Ad-IL15 (5 × 10⁸ PFU) every other day for a total of three injections. (a)The tumor growth in mice treated with PBS, Ad or Ad-IL15 was shown. n = 7–8. **P < .01, ***P < .001 and ****P < .0001 by an unpaired t test. (b - e) Eleven days after the last treatment, tumors were collected and analyzed by flow cytometry to calculate the percentages of TILs in the tumors. (b to c) Intratumoral CD45⁺ cells, CD8⁺ T cells, TRM cells, CD4⁺ T cells, NK cells, and NKT cells in B16-F10 (b) and MC-38 (c) tumor models. (d - e) Intratumoral CD8⁺CD69⁺T cells and CD8⁺PD-1⁺ T cells in B16-F10 (d) and MC-38 (e) tumor models. n = 5–8. * P < .05, **P < .01 and ***P < .001 by the Mann-Whitney U test. ns, not significant.